TY - JOUR
T1 - Fifteen years and 382 extended right grafts from in situ split livers in a multicenter study
T2 - Are these still extended criteria liver grafts?
AU - Maggi, Umberto
AU - De Feo, Tullia M.
AU - Andorno, Enzo
AU - Cillo, Umberto
AU - De Carlis, Luciano
AU - Colledan, Michele
AU - Burra, Patrizia
AU - De Fazio, Nicola
AU - Rossi, Giorgio
PY - 2015/4/1
Y1 - 2015/4/1
N2 - In situ split liver extended right grafts (SL-ERGs) are still considered marginal grafts. Our aim was to verify this statement at the present time. From 1997 to 2011, a multicenter, retrospective study based on a prospective database was performed at 9 liver transplantation (LT) centers in northern Italy; it included 382 in situ SL-ERG transplants in adults. There were 358 primary LTs and 24 retransplantations (RETXs). The 1-, 3-, and 5-year overall graft survival rate for LT with in situ SL-ERGs were 73.5%, 63.3%, and 60.7%, respectively, from 1997 to 2004 and 83.5%, 80.3%, and 80.3%, respectively, thereafter (P=0.0001). A shorter total ischemia time and fewer RETX grafts were the main differences between the characteristics of the 2 periods. From 1997 to 2011, the 1-, 3-, and 5-year graft survival rates showed a significant difference between the 358 primary LT in situ SL-ERGs and the 24 RETX in situ SL-ERGs (P60 years, RETX grafts, and urgency were the main prognostic factors for failure for all of the grafts. Although caution should be taken regarding the choice of appropriate donors, in situ SL-ERGs should no longer be considered marginal grafts for experienced LT centers. SL-ERGs should not be used in RETX settings, and when SL-ERGs are used as primary grafts, the total ischemia time should be less than 8 hours. Liver Transpl 21:500-511, 2015.
AB - In situ split liver extended right grafts (SL-ERGs) are still considered marginal grafts. Our aim was to verify this statement at the present time. From 1997 to 2011, a multicenter, retrospective study based on a prospective database was performed at 9 liver transplantation (LT) centers in northern Italy; it included 382 in situ SL-ERG transplants in adults. There were 358 primary LTs and 24 retransplantations (RETXs). The 1-, 3-, and 5-year overall graft survival rate for LT with in situ SL-ERGs were 73.5%, 63.3%, and 60.7%, respectively, from 1997 to 2004 and 83.5%, 80.3%, and 80.3%, respectively, thereafter (P=0.0001). A shorter total ischemia time and fewer RETX grafts were the main differences between the characteristics of the 2 periods. From 1997 to 2011, the 1-, 3-, and 5-year graft survival rates showed a significant difference between the 358 primary LT in situ SL-ERGs and the 24 RETX in situ SL-ERGs (P60 years, RETX grafts, and urgency were the main prognostic factors for failure for all of the grafts. Although caution should be taken regarding the choice of appropriate donors, in situ SL-ERGs should no longer be considered marginal grafts for experienced LT centers. SL-ERGs should not be used in RETX settings, and when SL-ERGs are used as primary grafts, the total ischemia time should be less than 8 hours. Liver Transpl 21:500-511, 2015.
UR - http://www.scopus.com/inward/record.url?scp=84925845370&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925845370&partnerID=8YFLogxK
U2 - 10.1002/lt.24070
DO - 10.1002/lt.24070
M3 - Article
C2 - 25545700
AN - SCOPUS:84925845370
SN - 1527-6465
VL - 21
SP - 500
EP - 511
JO - Liver Transplantation
JF - Liver Transplantation
IS - 4
ER -